雷贝拉唑治疗胃溃疡的临床观察

Clinical observation of rabeprazole in the treatment of gastric ulcer

目的探讨雷贝拉唑治疗胃溃疡的临床效果。方法此次依不同治疗方案将2015年1月～2017年3月于本院诊治的胃溃疡患者120例分组为：对照组用阿莫西林+克拉霉素+奥美拉唑治疗，观察组用阿莫西林+克拉霉素+雷贝拉唑治疗；详细观察2组患者治疗前后临床症状评分变化情况、IL-2/IL-6/CRP水平变化情况、不良反应发生情况，并将所获相关数据作对比分析。结果阿莫西林+克拉霉素+雷贝拉唑（观察组）治疗胃溃疡的效果优于阿莫西林+克拉霉素+奥美拉唑（对照组）治疗效果，患者临床症状评分变化情况优于对照组、IL-2/IL-6/CRP水平变化情况优于对照组，差异有统计学意义（P＜0.05）；2组患者不良反应发生率比较，差异无统计学意义。结论胃溃疡患者选择阿莫西林+克拉霉素+雷贝拉唑治疗的效果显著，可充分改善患者临床症状、IL-2/IL-6/CRP水平，并不会提高不良反应发生率，值得临床上广泛用来治疗胃溃疡患者。

Objective To investigate the clinical effect of Bella in the treatment of gastric ulcer.Methods According to the different treatmentmethods will be January2015-2017year in March in our hospital120cases of patients with gastric ulcer group:control group was treated withamoxicillin+clarithromycin+omeprazole treatment,the observation group used amoxicillin+clarithromycin+ray Bela with before and aftertreatment;the two groups were observed for clinical symptom score changes,the level of IL-2/IL-6/CRP the incidence of adverse reactions,and therelevant data for comparative analysis.Results Amoxicillin+clarithromycin+ray was Bella(observation group)in the treatment of gastric ulceris better than omeprazole+amoxicillin+clarithromycin(control group)treatment,clinical symptoms score changes better than the control group,IL-2/IL-6/CRP levels than the control group,the difference was statistically significant(P<0.05);two groups of patients the adverse reaction ratecomparison,the difference was not statistically significant.Conclusion The gastric ulcer patients choose amoxicillin+clarithromycin+ray Bellawith significant curative effect,can improve the clinical symptoms and IL-2/IL-6/CRP level of patients,and will not increase the incidence of adversereactions,it is worthy of widely used in the treatment of patients with gastric ulcer.